Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2013

View Archived Issues

Development of a potassium channel activator for the treatment of migraine

Novel phosphate adsorbers for the treatment of patients with renal failure

miRNA improves survival in a murine model of ALS

Development of two novel murine models of filarial pathology

Biotest and EpiVax to develop non-immunogenic treatment for hemophilia A

Stallergenes and ActoGeniX to develop treatments for allergic diseases

OncoMed and Celgene sign agreement for anti-cancer stem cell product candidates

Anti-infective startup company Auspherix launched

RXi Pharmaceuticals reports additional data from phase I RXI-109 trial

Genentech begins phase II trial of DNIB-0600A

Novel Nampt inhibitors presented by AbbVie

Novel muscarinic M4 positive allosteric modulator for the treatment of Huntington's disease

Incyte Corp. presents new JAK1 inhibitors

Researchers at Actelion Pharmaceuticals synthesize novel LXA4 receptor agonists

Idera Pharmaceuticals opens enrollment in phase I/II trial of IMO-8400

Glenmark Pharmaceuticals discloses novel ROR-gamma modulators

GlaxoSmithKline patents new EZH2 inhibitors for cancer

Bristol-Myers Squibb synthesizes new GPR119 receptor agonists

3-V Biosciences begins phase I TVB-2640 trial

Galapagos reports phase I findings on GLPG-1205

Sanofi launches ComPlavin combination tablets in Japan

Topline data reported from phase II study of ChemoCentryx's CCX-168

FDA grants orphan drug designation to Immunomedics' IMMU-132 for SCLC

The Medicines Company gains anti-infective assets through Rempex acquisition

Puma Biotechnology reports data from I-SPY 2 trial of neratinib

OncoMed studies vantictumab combination therapy for pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...